These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16675577)

  • 1. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.
    Vuylsteke RJ; Molenkamp BG; van Leeuwen PA; Meijer S; Wijnands PG; Haanen JB; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2006 May; 12(9):2826-33. PubMed ID: 16675577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
    Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.
    Molenkamp BG; van Leeuwen PA; Meijer S; Sluijter BJ; Wijnands PG; Baars A; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2007 May; 13(10):2961-9. PubMed ID: 17504997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma.
    Vuylsteke RJ; Molenkamp BG; Gietema HA; van Leeuwen PA; Wijnands PG; Vos W; van Diest PJ; Scheper RJ; Meijer S; de Gruijl TD
    Cancer Res; 2004 Nov; 64(22):8456-60. PubMed ID: 15548718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
    van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
    Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
    Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects.
    Bowne WB; Wolchok JD; Hawkins WG; Srinivasan R; Gregor P; Blachere NE; Moroi Y; Engelhorn ME; Houghton AN; Lewis JJ
    Cytokines Cell Mol Ther; 1999 Dec; 5(4):217-25. PubMed ID: 10850386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
    Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ
    Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.
    Dubsky P; Saito H; Leogier M; Dantin C; Connolly JE; Banchereau J; Palucka AK
    Eur J Immunol; 2007 Jun; 37(6):1678-90. PubMed ID: 17492620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
    Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
    Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
    Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
    Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
    Schaed SG; Klimek VM; Panageas KS; Musselli CM; Butterworth L; Hwu WJ; Livingston PO; Williams L; Lewis JJ; Houghton AN; Chapman PB
    Clin Cancer Res; 2002 May; 8(5):967-72. PubMed ID: 12006508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
    Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
    J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
    von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
    Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
    ; Celis E
    Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes.
    Lee JH; Torisu-Itakara H; Cochran AJ; Kadison A; Huynh Y; Morton DL; Essner R
    Clin Cancer Res; 2005 Jan; 11(1):107-12. PubMed ID: 15671534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.